Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study

Timo Vesikari, Ray Borrow, Aino Forsten, Helen Findlow, Mandeep S Dhingra, Emilia Jordanov, Timo Vesikari, Ray Borrow, Aino Forsten, Helen Findlow, Mandeep S Dhingra, Emilia Jordanov

Abstract

can lead to invasive meningococcal disease to which young children are particularly vulnerable. We assessed the immunogenicity and safety of Sanofi Pasteur's investigational quadrivalent (serogroups A, C, Y, and W) meningococcal tetanus-toxoid conjugate vaccine, MenACYW-TT, as a single dose, in healthy meningococcal vaccine-naïve toddlers versus a licensed conjugate vaccine MCV4-TT (NCT03205358). In this Phase II study conducted in Finland, 188 toddlers aged 12-24 months were randomized 1:1 to MenACYW-TT or MCV4-TT. Serum bactericidal antibody assays using human complement (hSBA) and baby rabbit complement (rSBA) measured antibodies against each serogroup before and 30 days after vaccination. Participants were monitored for immediate adverse events (AEs) and post-vaccination AEs for 30 days. All analyses were descriptive. All 188 participants completed the study. The Day 30 hSBA seroresponses (hSBA titer <8 at baseline and post-vaccination titer ≥8, or ≥8 at baseline and ≥4-fold increase post-vaccination) were comparable between participants receiving MenACYW-TT (96.7-100%), and MCV4-TT (86.0-100.0%) for each serogroup. Most unsolicited AEs were of Grade 1 or Grade 2 intensity. There were no immediate hypersensitivity reactions, and no AEs or serious AEs leading to discontinuation from the study. In this exploratory study, MenACYW-TT vaccine was well tolerated and immunogenic. If confirmed in Phase III, a single dose of the MenACYW-TT vaccine may show promise as an alternative vaccine option for toddlers receiving meningococcal vaccination for the first time.

Keywords: Meningococcal; menACYW-TT; quadrivalent meningococcal conjugate vaccine; toddlers.

Figures

Figure 1.
Figure 1.
Study groups and protocol deviations.
Figure 2.
Figure 2.
Proportion of participants with vaccine seroresponse at Day 30, against meningococcal serogroups A, C, W, and Y (PPAS) as assessed by (A) hSBA* and (B) rSBA†.

References

    1. Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
    1. Rouphael NG, Stephens DS.. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
    1. Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L, Kanitz E, Richter L, Mattheus W, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35:2034–41. doi:10.1016/j.vaccine.2017.03.007.
    1. Chang Q, Tzeng YL, Stephens DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:237–45. doi:10.2147/CLEP.S28410.
    1. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:17. doi:10.1186/1478-7954-11-17.
    1. Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59:S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
    1. Maiden MCJ. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philos Trans R Soc Lond B Biol Sci. 2013;368:20120147. doi:10.1098/rstb.2012.0147.
    1. Control ECfDPa . Disease data from ECDC Surveillance Atlas for meningococcal disease. Solna (Sweden): European Centre for Disease Prevention and Control; 2017.
    1. Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2:e473–e482. doi:10.1016/S2468-2667(17)30157-3.
    1. World Health Organization . Meningococcal vaccines: WHO position paper, November 2011. Weekly epidemiological record: No.47. 2001;86:521–40.
    1. Sanofi Pasteur Inc . 284 Menactra® Highlights of prescribing information. Lyon (France): Menactra® (package insert); 2018.
    1. Serra LC, York LJ, Gamil A, Balmer P, Webber C. A review of meningococcal disease and vaccination recommendations for travelers. Infect Dis Ther. 2018;7:219–34. doi:10.1007/s40121-018-0196-z.
    1. Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine. 2018;36:5470–76. doi:10.1016/j.vaccine.2017.07.056.
    1. Gonococcal vaccine development: lessons from group B meningococcal vaccines. EBioMedicine. 2017;22:1. doi:10.1016/j.ebiom.2017.07.026.
    1. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26. doi:10.1084/jem.129.6.1307.
    1. Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccine Immunother. 2019;15:1–10.
    1. Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31:1173–83. doi:10.1097/INF.0b013e318268dfe4.
    1. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagn Lab Immunol. 1997;4:156–67. doi:10.1128/CDLI.4.2.156-167.1997.
    1. Findlow H, Plikaytis BD, Aase A, Bash MC, Chadha H, Elie C, Laher G, Martinez J, Herstad T, Newton E, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin Vaccine Immunol. 2009;16:969–77. doi:10.1128/CVI.00068-09.
    1. McIntosh ED, Broker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays - The role of complement in infection and immunity. Vaccine. 2015;33:4414–21. doi:10.1016/j.vaccine.2015.07.019.
    1. Welsch JA, Ram S. Factor H and neisserial pathogenesis. Vaccine. 2008;26(Suppl 8):I40–5. doi:10.1016/j.vaccine.2008.11.060.
    1. Bilukha OO, Rosenstein N.. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 2005;54:1–21.
    1. European Medicines Agency . Assessment report for Menveo. Amsterdam, The Netherlands: EMA; 2010.
    1. European Medicines Agency . Assessment report: Nimenrix. Amsterdam, The Netherlands: EMA; 2012.
    1. Borrow R, Tang Y, Yakubu A, Kulkarni PS, LaForce FM. MenAfriVac as an antitetanus vaccine. Clin Infect Dis. 2015;61:S570–S7. doi:10.1093/cid/civ512.
    1. Deeks ED. Meningococcal quadrivalent (Serogroups A, C,W135, and Y) conjugate vaccine (Menveo®). BioDrugs. 2010;24:287–97. doi:10.2165/11204790-000000000-00000.
    1. Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, Martin S, Thornton C, Goldblatt D, Corbel M, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun. 2002;70:4946–54. doi:10.1128/IAI.70.9.4946-4954.2002.
    1. European Centre for Disease Prevention and Control . Invasive meningococcal disease. Stockholm (Sweden): ECDC. Annual Epidemiological Report for 2015; 2017.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit